The Practitioners You’re Missing

Like MDs, NPs and PAs prescribe in nearly every specialty and practice setting. NPs/PAs are seen for over 19 million Emergency Department visits per year, 40% of which don’t involve MDs. Over 20,000 PAs practice in surgery and nearly 10,000 in emergency medicine. NPs and PAs see more patients than physicians for some fields and conditions such as pediatrics, depression and obesity. Most patients put just as much trust in NPs/PAs as they do in MDs. Don’t undervalue the large and growing NP/PA prescriber segment. Continue reading…

FacebookTwitter

NPs Replacing MDs

As of today 30% of U.S. providers are nurse practitioners (NPs) or physician assistants (PAs) which is up from 24% in 2010. By 2025, NPs and PAs are expected to make up an even greater portion of providers because MDs are growing at a slower pace. Continue reading…

FacebookTwitter

Two Strategies for Drug Pricing

The media has recently vilified pharma companies for drug price increases. For example, EpiPen’s rise in price from around $100 for a 2-pack to about $600 in 2016 was national news with the CEO harshly criticized by high profile politicians as well as the public and media. Many other medications have also had dramatic price increases including a popular injectable version of Naloxone for opioid overdose which has had a more than 1000% price increase over the last decade. Continue reading…

FacebookTwitter

Pharma: Can Tweet Chats Help You?

Boehringer Ingelheim’s #ChatAfib won the Excellence in Digital Communications award and #COPDChat was used by Twitter as a tweet chat success story case study. In 2013, Boehringer hosted its first tweet chat (#ChatAfib) during the European Society of Cardiology Congress and participants included HCPs, patients and patient groups. Pfizer, Novartis, Celgene, Takeda, Sanofi and Johnson and Johnson have all since successfully hosted tweet chats. Continue reading…

FacebookTwitter

Did Your Pharma Company Miss Out Not Having a Super Bowl Ad?

In 2017 pharma companies made a wise decision to stay away from Super Bowl ads. In 2015, an ad for a medication to treat toenail fungus ranked 60 out of 61 on USA Today’s consumer-rated Super Bowl ads. In 2016, three medication ads ranked 60, 62 and 63 out of 63 – again being called among the worst. In fact, pharma companies were criticized for these Super Bowl ads. Continue reading…

FacebookTwitter
1 6 7 8 9 10 12